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myocardial infarction (78% versus 68%; P < 0.001). Even after multivariate adjust-
ment, MS was still associated with higher risk of in-hospital heart failure (odds ratio 
(OR), 1.37; 95% CI: 1.03–1.81; p = 0.028) and mortality (OR, 4.42; 95% CI: 
1.25–15.5; p = 0.020). CONCLUSIONS: Prevalence of MS in ACS patients in Oman 
is high and seen more in females than in males. Furthermore, MS was associated with 
higher in-hospital heart failure and mortality.
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OBJECTIVES: Despite the availability of the ESC European guidelines on cardiovas-
cular prevention, considerable cardiovascular mortality remains throughout Europe. 
The European Study on Cardiovascular Risk Prevention and Management in Daily 
Practice (EURIKA) (NCT00882336) investigated the prevalence and degree of control 
of main cardiovascular risk factors in primary prevention of cardiovascular disease 
(CVD). METHODS: EURIKA was a cross-sectional study conducted simultaneously 
in 12 European countries (n = 809 primary care and specialist physicians). Patients 
aged ≥50 years who were free of clinical CVD, but had at least one risk factor as 
deﬁ ned by the 2007 European guidelines on cardiovascular prevention, were eligible 
for inclusion. Data recorded included smoking status, body mass index, cholesterol 
levels, blood pressure and presence of diabetes. Cardiovascular risk was assessed by 
Systematic COronary Risk Evaluation (SCORE) methods. Attributable coronary mor-
tality was calculated based on our prevalence estimates together with hazard ratios 
for CVD-related mortality (from the Third National Health and Nutrition Examina-
tion Survey). RESULTS: In total, 7641 patients (mean age: 65 years; 48% male) were 
evaluated. Of those aged <65 years, 27% had a SCORE-based absolute risk of CVD 
of ≥5%. The prevalence of risk factors was 21.3% for current smoking, 71.9% for 
hypertension, 55.4% for dyslipidemia, and 26.6% for diabetes. Control of risk factors 
among patients receiving therapy was 49% (between country range: 40–61%) for 
hypertension, 48% (26–74%) for dyslipidaemia and 40% (26–54%) for diabetes. The 
adjusted excess mortality attributable to risk factors was 17% (14–25%) for current 
smoking, 23% (21–25%) for hypertension, 26% (17–31%) for dyslipidaemia, and 
30% (20–37%) for diabetes. CONCLUSIONS: The prevalence of traditional cardio-
vascular risk factors is high and their control is suboptimal. Traditional risk factors 
such as hypertension, dyslipidaemia and diabetes are responsible for a large fraction 
of the estimated coronary deaths that could be avoided through primary prevention.
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OBJECTIVES: This study aims to determine the degree of blood pressure (BP) control 
and the differences in therapeutic strategies adopted by physicians based on patients’ 
age and/or their functional status. METHODS: Multicenter and cross-sectional study 
that included patients with essential hypertension attending primary or specialist care, 
with at least one year of evolution. The study included 6453 patients, stratiﬁ ed into 
three main groups: a (<65 years) = 2184; B (65–79 years) = 2079; and C (≥80 years) 
= 2079. RESULTS: 51.3% of patients were male and mean (SD) age was 55.1 ± 7.5 
years (group A), 71.4 ± 4.0 (B) and 83.7 ± 3.2 (C). 49.1% of patients were overweight. 
Mean systolic BP values were 141.3 ± 15.6 (A), 142.0 ± 16.3 (B) and 142.3 ± 16.8 
(C) mmHg, and mean diastolic BP values were 84.5 ± 10.1 (A), 81.5 ± 10.5, 79.9 ± 
11.2 (C) mmHg. 33.5% of patients had type 2 diabetes mellitus and 59.1% dyslipid-
emia. The existence of previous cardiovascular (CVD) or renal disease has been 
established in 38.9% of cases. The prevalence of CVD was 22.6% (A), 39.1% (B) and 
55.9% (C). Target organ damage (TOD) was 26.7% (A), 40.8% (B) and 57.8% (C). 
The Barthel index that measures a person’s daily functioning reﬂ ected that the oldest 
group had a signiﬁ cantly higher level of moderate or severe dependence (P < 0.0001). 
Patients with controlled BP were 29.4% (A), 25.5% (B) and 23.7% (C) (P < 0.0001). 
Clinical inertia—the failure to intensify therapy in patients who do not achieve the 
clinical objectives—reached 60.3% (A), 61.7% (B) and 66.2% (C) (p = 0.0002), 
respectively. Global treatment compliance was 94.3%, and the difﬁ culty for taking 
the medication signiﬁ cantly increased with patients’ age (P < 0.0001). CONCLU-
SIONS: Older hypertensive patients have a poorer BP control but an increased clinical 
inertia. These patients have higher prevalence of TOD and CVD, worse functional 
status and worse treatment compliance. 
CARDIOVASCULAR DISORDERS – Cost Studies
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OBJECTIVES: The self-expandable paclitaxel DES represents a major development in 
endovascular treatments for lower limb PAD. Clinical data show improved clinical 
outcomes compared to bare metal stents (BMS). This budget impact analysis assessed 
the impact of introducing reimbursement for a paclitaxel DES in France. METHODS: 
An Excel-based model was developed to estimate the impact of a transition from BMS 
to DES over a 5-year horizon (15% in 2011 to 35% in 2015). Hospital episode sta-
tistics were used to estimate the 2011–2015 patient population. The analysis was 
conducted from the payer perspective and only direct costs of procedures were con-
sidered, based on GHM 2009 tariffs (stenting and revascularization) and LPPR tariffs 
(BMS and grafts). The main outcome was target lesion revascularization (TLR) in the 
superﬁ cial femoral artery (SFA) after primary stent placement: angioplasty, re-stenting, 
or bypass surgery. TLR rates were based on the paclitaxel drug-eluting SFA stent 
registry study and on BMS TLR rates reported in the literature (Years 1 and 2: 6% 
and 9% for the DES; 16% and 22% for average BMS) and extrapolated for years 3 
to 5. Net budget impact was expressed as the difference in cost between the scenario 
where the DES is progressively adopted versus the status quo (patients treated with 
BMS only). RESULTS: The base-case results show an incremental cost of c278,526 
in year 1, which is more than offset by increasing cost savings in all subsequent years 
(year 2: −c35,901; year 5: −c510,025), resulting in a cumulative 5-year net budget 
impact of −c727,649. One-way sensitivity analyses on key inputs continued to show 
cumulative 5-year cost savings. CONCLUSIONS: Reimbursement and consequent 
adoption of the paclitaxel DES would result in cost savings for the French health care 
payer, despite requiring an initial investment. This is due to savings associated with 
fewer SFA revascularization events after the primary intervention.
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OBJECTIVES: Aortic Stenosis (AS) is a severe cardiovascular condition and treatment 
often involves a major operation. For a subgroup of patients medical management 
(MM) is the only treatment option due to procedural risk. A transcatheter aortic valve 
implantation device “CoreValve,” is less invasive and allows for the implantation of 
a replacement valve in this patient group. However, CoreValve is more expensive than 
MM and introducing this technology into routine care would lead to an increase in 
National Health Service (NHS) spending. We estimated this budgetary impact using 
existing economic models. METHODS: In an Excel based Markov model CoreValve 
was compared to MM for inoperable patients. Parameters were derived from pub-
lished literature. Costs were taken from the most recent published sources. Decrements 
were applied to age-speciﬁ c EQ-5D population norms to generate QALYs. Incidence 
estimates were derived from information in a large national database. Projected ﬁ ve 
year uptake rates were provided by Medtronic. The outputs from the economic model 
were used for all relevant parameters. Case mix estimates were elicited from a clinical 
advisory board. RESULTS: Across all patients, the estimated incidence rate of AS was 
165 per million, 40% of these patients were assumed to be inoperable, 66 per million. 
The uptake rate of CoreValve in the inoperable group rose linearly from 0% to 50% 
over 5 years. When all inoperable patients were treated with MM the total budgetary 
cost was £13,454,000. When 50% of patients are treated with CoreValve and 50% 
with MM, the total budgetary cost increases to £49,706,000. Thus, the total burden 
to the NHS of 50% of inoperable patients receiving CoreValve would be £36,251,000. 
With a more optimistic ﬁ ve year uptake rate (75%) this increases to £54,852,000. 
CONCLUSIONS: Introducing CoreValve would result in an additional £36,251,000 
being spent by the UK NHS.
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OBJECTIVES: To calculate and compare costs of primary treatment of hypertension 
with candesartan/hydrochlorothiazide (HCT) or losartan/HCT in the Mexican Social 
Security Institute (IMSS). METHODS: An adaptation from Kjeldsen observational 
study of 14,100 patients diagnosed with hypertension and the costs’ sub analysis of 
Henriksson was made to have an approximation of incurred costs by IMSS when using 
candesartan/HCT or losartan/HCT in the primary hypertension treatment and its 
impact in reducing related cardiovascular events. First assumption for adaptation was 
to use only costs of combined therapies with HCT since monotherapies are not 
included in the IMSS formulary. Hospitalizations, laboratory tests and physician visits 
resource consumption reported by Kjeldsen were multiplied by IMSS 2010 unit costs. 
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An average of 3.35 years follow-up was used. IMSS population with hypertension was 
estimated using the national prevalence of 30.8% (20 years and older) reported by 
the National Health Survey of 2006, the proportion (70%) of the Mexican population 
over 20 years old reported by the National Population Council and the number of 
total IMSS afﬁ liates. a 5% discount rate was applied to costs. Results are presented 
in US dollars (exchange rate 13 MXN/dollar). RESULTS: Primary hypertension 
annual treatment cost per patient including related cardiovascular events was $556.56 
for patients treated with candesartan/HCT and $718.42 with losartan/HCT treatment. 
Theoretical savings yield by candesartan/HCT are $161.86 per patient. Calculated 
hypertension patients afﬁ liated to the IMSS was 10 million. Average annual savings 
given this population are $1.707 million for the institution with 1.8 million bed days, 
4.4 million physician visits and 5.3 million laboratory tests avoided. CONCLUSIONS: 
This analysis showed that the reduction of cardiovascular events with the use of 
candesartan/HCT for treating primary hypertension could save $1.707 million to the 
IMSS.
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OBJECTIVES: To evaluate the costs of ambrisentan within therapeutic health 
program in 2nd phase line treatment of adult patients with idiopathic, familiar or 
associated with connective tissue disease pulmonary hypertension of III NYHA stage. 
METHODS: The analysis compared two scenarios: existing and new. The existing 
one assumed application of bosentan, iloprost, treprostinil or sildenaﬁ l in patients with 
pulmonary hypertension of III NYHA stage in case of 1st line treatment with bosentan 
or sildenaﬁ l failure. The new one included also administration of ambrisentan. Popula-
tion’s abundance and market shares of drugs used in presented indication were esti-
mated on the basis of PHPOL Registry. Cost data were collected from public payer’s 
perspective (National Health Fund) in Poland and calculated in ﬁ ve years horizon. 
Ofﬁ cial ex factore price of Volibris® was provided by the producer. Cost analysis was 
performed under assumption that ambrisentan would be ﬁ nanced within the frame-
work of Catalogue of active substances used in therapeutic health programs. a range 
of variables was checked in a sensitivity analysis. RESULTS: Introduction of ambris-
entan to Catalogue of active substances used in therapeutic health programs and 
administration in 2nd line treatment of adult patients with idiopathic, familiar or 
associated with connective tissue disease pulmonary hypertension of III NYHA stage 
brought savings from public payer’s perspective amounted to: 178,782PLN 
(64,719PLN–342,497PLN) in ﬁ rst year, 385,054PLN (132,673PLN–769,277PLN) in 
second year, 614,006PLN (203,224PLN–1,266,372PLN) in third year, 646,137PLN 
(206,854PLN–1 366,336PLN) in fourth year and 674,573PLN (210,053PLN–
1,455,310PLN) in ﬁ fth following year. CONCLUSIONS: Treatment with ambrisentan 
leads to savings from public payer’s perspective and constitutes substantial therapeutic 
achievement (it is administered orally and only once a day unlike other drugs currently 
used in presented indication).
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OBJECTIVES: The purpose of this study was to perform comparative pharmacoeco-
nomic analysis of antithrombotic therapy with rivaroxaban (Xarelto®) and enoxapa-
rin (Clexane®) in the conditions of real clinical practice of total hip (THR) and knee 
(TKR) replacement. METHODS: The method of budget impact modeling was used. 
RESULTS: At equal duration of venous thromboembolism (VTE) prophylaxis at THR 
(35 days) rivaroxaban turned out to be more budget saving than enoxaparin by 2399 
RUB (62.71c), reducing the quantity of complications cases (pulmonary embolism, 
deep venous thrombosis, death) by 26 cases per one thousand patients. At various 
duration of prophylaxis at THR—rivaroxaban (35 days) and enoxaparin (14 days)—
rivaroxaban application has also demonstrated budget savings by 100 RUB(2.63c) 
thus reducing the quantity of complications by 74 cases per one thousand patients. 
The results of comparison of two weeks VTE prophylaxis after TKR have shown the 
most sizeable economy after rivaroxaban application by 7734 RUB(202.164c) and 
simultaneous complications decrease by 92 cases per one thousand patients. CON-
CLUSIONS: Rivaroxaban demonstrated budget savings compared to enoxaparin at 
all prophylaxis regiments at THR and TKR by reducing thrombosis complications.
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OBJECTIVES: AF is a big problem of the Russian Health Care System because cardio-
vascular diseases are the leaders in the structure of morbidity and mortality. Systemic 
statistics of AF and AF BI are unknown. Aim: To calculate the AF BI based on regional 
data and extrapolate the received data for Russia. METHODS: Evaluation of AF 
incidence and prevalence in dynamic (1995–2005) in the North-West region of Russia, 
calculation of direct and indirect costs and perspective modeling. RESULTS: As 
estimation—AF prevalence in Russia is 3.2/1000, incidence is 1,766/100,000, parox-
ysmal and persistent AF are increased from 0.6 to 1.8 and 0.25 to 0.6/1,000 accord-
ingly. Hypertension (73%), ischemic hart disease (65.2%), diabetes (9%) occurred in 
the ﬁ rst episode of AF. Hospitalization rate is increased by 66%, estimated rate is 
1.23 mln. pts./year, and it’s length is 6.9 days on the average, AF lethality is 1%. 
Disability rate is 40%, estimated amount of disability days is 3.3 mln/year. Calculated 
hospitalization cost for one year is 11.35 bln RUR (~c298 mln), cost for out-patients’ 
day-service—29.6 mln RUR (~c778 ths) and cost of out-patient treatment for all 
patients is no less than 32.5 bln RUR (c855 mln) including drugs cost—19.6 bln RUR 
(Euro). Estimated surgery cost is 260 mln RUR (c6.8 mln). Undirected adjusted cost 
is no less than 3 bln RUR (~c80 mln). CONCLUSIONS: AF BI in the Russian Federa-
tion leads to the biggest governmental, insurance and personal expenditures as com-
pared to the developed countries. Annual BI AF without deﬁ ciancial GDP per person 
is no less than c5.5 ths. Decreasing of AF BI can be particularly achieved in case of a 
better pharmaceutical control of AF aimed at saving budget charges due to the less 
hospitalization and surgeon rates.
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OBJECTIVES: The majority of cardiac device recipients are routinely followed. 
Implantable Cardioverter Deﬁ brillators (ICDs) devices must be systematically and 
continually monitored, with follow-up frequency adjusted for the patient’s underlying 
medical condition, device-related issues, and patient preferences. In México, in CMN-
IMSS La Raza, the current implant rate for ICD is 5 per million (equating to 30 new 
implants per year) and every year an average of 180 patients implanted with ICD are 
attending follow-up visits at La Raza hospital in Mexico. This simulation provides 
evidence to support the use of remote follow up and monitoring of ICDs via the 
CareLink Network as an alternative to follow-up consultations in attending an out-
patient clinic setting. METHODS: The simulation considers patients implanted with 
ICD (without CareLink) will on average require 4 in-clinic follow-up consultations 
per year whilst those with CareLink will only require 1 in-clinic follow-up consultation 
(4–6 weeks post implant) and 3 remote follow-up consultations. Reviewing patient 
data provided via the CareLink Network (remote monitoring consultation) requires 
an average 8.4 minutes of cardiac physiologist time compared to 25.8 minutes for an 
in–clinic follow-up consultation. RESULTS: For each patient per year the introduction 
of a remote monitor to support device follow-ups, lead to a reduction in cardiac 
physiologist time of 52.2 minutes equivalent to $17,970 MXP ($30,686 MXP without 
CareLink versus $12,716 MXP on CareLink). The cost of a cardiac physiologist time 
is $2630.00 MXP (per hour) equating to MXP 368.20 per remote follow-up versus 
$1130.90 MXP per in-clinic follow-up. CONCLUSIONS: The use of CareLink can 
potentially generate economic beneﬁ ts for the health professional, institution, health 
system and the patient.
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OBJECTIVES: To develop a model to assess the clinical and economic impact of a 
pocket-sized ultrasound (PSU) versus standard ultrasound for abdominal aortic aneu-
rysm (AAA) screening in Italy. METHODS: The model was developed from the 
perspective of the Servizio Sanitario Nazionale, the national health care system in Italy, 
during an 8-year time horizon for 65–74-year-old males who had smoked in their 
lifetime. Our model assumed 100% of eligible males could be screened with the PSU, 
as compared to 29% actually screened with standard ultrasound, and that screening 
with a PSU would incur no additional cost. Model inputs were derived from major 
clinical trials (4-year rates of mortality, aortic rupture, and elective and emergency 
surgeries) and DRG reimbursement rates (costs). Model outputs of number of deaths, 
ruptures and costs (2010 euros) were calculated. One-way sensitivity analyses were 
conducted. RESULTS: A PSU strategy yielded a 33.8% (0.32% vs. 0.48%) and 46.6% 
